musc.edu.2Department of Psychology, Auburn University, 226 Thach Hall, AL 36849, USA.3Department of Psychiatry and Behavioral Sciences, Medical Unviersity of South Carolina, 67 President Street, Charleston, SC 29425, USA; Ralph H. Johnson VAMC, 109 Bee Street, Charleston, SC 29401, USA.AbstractBACKGROUND:

Sex differences in cannabis use disorder (CUD) and its treatment have been identified. Women report more severe withdrawal and have shown worse treatment outcomes. Ovarian hormones are implicated in these differences and research suggests that exogenous progesterone may be an effective pharmacotherapy.

METHODS:

The current randomized, placebo-controlled, feasibility trial tested a novel multimodal methodology for administering exogenous progesterone during acute cannabis withdrawal. Eight heavy cannabis using women received micronized progesterone (200 mg bid) (n 

View the Original article

Partage le savoir
error: Content is protected !!